Shuttle Pharmaceuticals Holdings Inc (SHPH) Quote

SHPH...............................................................https://stockcharts.com/h-sc/ui?s=SHPH&p=W&b=5&g=0&id=p86431144783

Don’t blink…

This is setting for a squeeze......

LOL

Halt…

1.7 PM

Welp

SHPH 2.87 A/H

SHPH new 52 week low

needs big money for upcoming trials which means huge numbers of shares hitting the market soon. STRONG SELL!

I am sold out in premarket at 0.57 with news. feel luck. But Market open is different reaction to news. Very strange

Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Moving up, looks good.

SHPH new 52 week low

https://ih.advfn.com/stock-market/NASDAQ/shuttle-pharmaceuticals-SHPH/stock-news/92982458/form-8-k-current-report

Boom .62

MMs are playing game to sell or buy 1 shares to control PPS.

Unbelievable SHPH from $8 up to $126, then from $126 down to $0.48. What is real value? Now MC is only $8mm???? MMs are playing big game!!!

SHPH new 52 week low

ready to rebound from the bottom

news out today:
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that TCG GreenChem has successfully completed the initial manufacturing campaign for the active pharmaceutical ingredient (API) of Ropidoxuridine for use in the Company's upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy.

"Shuttle has been working concomitantly with TCG GreenChem to manufacture API and University of Iowa Pharmaceuticals to develop the formulation and packaging of the drug product into capsules for clinical use. Today's announcement of successfully completing the API manufacturing is an important step in the advancement Ropidoxuridine, our lead clinical sensitizer drug candidate, towards the commencement of our upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy," commented Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D.

In addition, Shuttle's recent request for a Type B pre-IND meeting with the FDA for guidance on the proposed Phase II clinical trial has been approved with a goal of receiving written responses from the FDA by September 18, 2023. With this, the Company believes it remains on track to commence its Phase II clinical study in the fourth quarter of 2023.

This news delayed one month already, It should be out soon, with this news PPS could be explode

See afternoon buy up as usual.

$SHPH: Tiny lil bounce here at 1.12 now


Sooooooooooooooooooooo...................... can it get to $3.50 ???


We shall see


GO $SHPH

Pay attention to these sentences, PPS will explode again.


With Ropidoxuridine, we are finalizing details to submit the final protocol details to the FDA at the end of the second quarter of 2023 with commencement of the Phase II clinical trial in brain cancer patients commencing shortly thereafter.

Shuttle Pharmaceuticals Provides Q1 2023 Corporate Update
3w
+2.88%
Recent Highlights

Shuttle Pharma continues to execute on the necessary steps to advance Ropidoxuridine, the Company's lead clinical sensitizer drug candidate, towards the commencement of its upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy with an expectation of pre-IND application submission to the FDA by the end of the second quarter of 2023.
Entered into agreements with TCG GreenChem, Inc. and UI Pharmaceuticals for drug manufacture and formulation development of Ropidoxuridine, the Company's lead clinical sensitizer drug candidate, for use in the Company's upcoming Phase II clinical trial evaluating Ropidoxuridine in combination with radiation therapy for the treatment of glioblastoma.
Engaged Theradex Oncology, a leading clinical research organization, to help prepare for its upcoming clinical study of Ropidoxuridine.
Entered into an agreement to lease new laboratory and office space, commencing in June 2023, to assist in furthering the development of the Company's lead drug candidates and accelerate broader diagnostic capabilities on predictive biomarkers.
Entered a research agreement with Georgetown University focused on the evaluation of the Company's lead HDAC6 inhibitor candidate, SP-2-225, evaluating the anti-tumor effect of the combination of SP-2-225 and RT in a syngeneic breast cancer model.
Shuttle Pharma was awarded U.S. Patent No. 11,654,157, "Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With Radiation," which was issued by the U.S. Patent and Trademark Office on May 23, 2023.
Published manuscripts discussing prostate cancer cell lines derived from African American men for precision medicine and immune responses taking place in patients after radiation therapy for cancer.
Awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform.
Appointed Dr. Bette Jacobs to its Board of Directors as an independent director.
Rang the Nasdaq opening bell in January 2023.
Closed on private placement of $4.3 Million of Senior Secured Convertible Note and Warrants to purchase 1.018 million shares of common stock in exchange for $4.0 million investment.
At March 31, 2023, the Company had a working capital balance of $9 million. The Company anticipates that it has sufficient capital to fund operations into the first quarter of 2025.
"Shuttle Pharma is advancing our mission to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of Radiation Therapy while limiting the late effects of radiation in cancer treatment," commented Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D. "During the first quarter, we made tangible progress advancing our pipeline, including Ropidoxuridine, our lead clinical drug candidate, which sensitizes rapidly growing cancer cells and, our various selective HDAC (histone deacetylase) inhibitors – which sensitize cancer cells and stimulate the immune system. With Ropidoxuridine, we are finalizing details to submit the final protocol details to the FDA at the end of the second quarter of 2023 with commencement of the Phase II clinical trial in brain cancer patients commencing shortly thereafter. Additionally, we are advancing pre-clinical work to support our IND-enabling studies in 2023 with a goal to submit an investigational new drug application (IND) for the selective HDAC6 inhibitor and initiation of a Phase I clinical trial in 2024. We look forward to an exciting 2023 as we advance our immuno-oncology and radio-oncology solutions."

In siders own 47% shares

mAybe

insert dd

they pop big then consolidate 2 ,, 3 or 4 weeks then run again -insert DD-

looks like ready to move north

https://www.barchart.com/stocks/quotes/SHPH/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=SHPH&grid=1&height=500&studyheight=100

watching

keeping track of my 50 tickers, big runs, big dips then run higher

watching lots of one day wonders

SHPH: THANKS for that!!

SHPH trading up to $2+ at today's pre market.

SHPH: And THANKS again, Boss!!

Quarterly Report (10-q)
https://ih.advfn.com/stock-market/NASDAQ/shuttle-pharmaceuticals-SHPH/stock-news/91166889/quarterly-report-10-q

Short becareful, Charts shows ready to big rebound.

Nonstop flight down I mean. This is perfect to short

good to short

Wow!

Yessss Sir, this shuttle is a non-stop flight

Right thru three bucks imo

: )

SHPH News
Shuttle Pharmaceuticals shares are trading higher after it was granted U.S. patent #11654157: Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation.
2h
+98.54%
Digest-only

where is the news?

Patent granted

Volume